Facts that can be checked side by side
Pharmacoeconomics is not “which pack costs less”
A cost-effectiveness study must define its population, market and currency, price or reimbursement source, capture date, regimen, outcomes, time horizon, resource use and uncertainty analysis. A one-off retail price, international conversion or direct division of different pack sizes is not a pharmacoeconomic conclusion.
- Currently publishable price records: 0. No price is displayed without market, currency, channel and date.
- Future price records must distinguish originator brand, generic, strength, pack, tax, prescription or OTC pathway and availability.
- Medicine or dose decisions belong with a clinician or pharmacist using the current label and individual context.
Price publication gate
Only complete records for the same market and the same product definition enter a comparison. If any field is missing, the platform does not calculate a unit cost or make a cross-market price conclusion.
- Target market and capture date
- Brand/generic name, approval record and originator or generic verification status
- Dosage form, route, strength and pack size
- Channel, prescription path and availability status
- Amount, currency, tax and reimbursement or discount basis
- Accessible source, collector and review version
How a U.S. per-unit benchmark is admitted
CMS NADAC can enter editorial review as a U.S. retail-community-pharmacy acquisition-cost benchmark per unit, on the official update cadence. It is not a retail price, patient out-of-pocket amount or reimbursement decision. Each row still needs an NDC-to-product identity match, current target-market label, dosage form, strength, pack and human review before it could be shown as public price material. Its rate-setting classification does not establish originator or generic identity.
Official price and reimbursement entry points
These entry points identify reviewable market-specific price or reimbursement bases. Until the product, presentation, date and source are reviewed together, the platform does not derive a price conclusion from them.
- United States · CMS / Medicaid NADAC: Weekly pharmacy acquisition-cost reference; not a retail, patient out-of-pocket or cross-channel price.
- United Kingdom (NHS England/Wales pathway) · NHSBSA Drug Tariff: NHS contractor reimbursement, fees and rules; not a private-prescription or retail price.
- Australia · Australian PBS Schedule: Government-subsidised schedule and its pricing basis; actual patient payment still depends on eligibility, premiums and pharmacy conditions.
- Japan · MHLW NHI drug-price notices: National insurance claim-price notices; they do not automatically equal an individual's payment.